Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifitegrast in allergic conjunctivitis
NCT00882687Phase 2Completed
- Sponsor
- Takeda
- Start
- Apr 2009
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lifitegrast in allergic conjunctivitis (AC) (4 arms), sponsored by Takeda. Primary endpoints: Ocular Itching at Day 7 (7 Minutes Post Conjunctival Allergen Challenge [CAC 6]), Ocular Itching at Day 14 (7 Minutes Post CAC 9) and 2 more. Started Apr 2009; status: completed.
02
Drugs
lifitegrast
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT00882687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00882687.